CAZZANIGA, MARINA ELENA

CAZZANIGA, MARINA ELENA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 139 (tempo di esecuzione: 0.036 secondi).
Titolo Tipologia Data di pubblicazione Autori File
A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial 01 - Articolo su rivista 2025 Cazzaniga, MECordani, NGalimberti, S +
Oral Anticancer Therapies: Addressing Nonadherence in Patients With Breast Cancer 01 - Articolo su rivista 2025 Cazzaniga M. E. +
Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC) 01 - Articolo su rivista 2025 Clementi, Thoma DarioCazzaniga, Marina Elena +
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 01 - Articolo su rivista 2025 Malighetti, FedericaVilla, MatteoPelucchi, SaraAroldi, AndreaCortinovis, Diego LuigiCazzaniga, Marina ElenaMologni, LucaRamazzotti, DanieleCordani, Nicoletta +
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13—AMBRA Study 01 - Articolo su rivista 2025 Cazzaniga M. E. +
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP) 01 - Articolo su rivista 2025 Cazzaniga M. +
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 01 - Articolo su rivista 2024 Cazzaniga M. E.Zambelli A. +
Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions(Front. Oncol., (2023), 13, (1249160), 10.3389/fonc.2023.1249160) 99 - Altro 2024 Cazzaniga M. +
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 01 - Articolo su rivista 2024 Ilari, AliceSherif, NoorhanGrassilli, EmanuelaRamazzotti, DanieleCordani, NicolettaCazzaniga, GiorgioDi Bella, CamilloLavitrano, MarialuisaCazzaniga, Marina ElenaCerrito, Maria Grazia +
Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection 01 - Articolo su rivista 2024 Foti G.Citerio G.Pesci A.Valsecchi M. G.Cazzaniga M.Bellani G.Bruno R.Biondi A.Bettini L. R.Beretta I. +
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer 01 - Articolo su rivista 2024 Cazzaniga M. E. +
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study 01 - Articolo su rivista 2024 Cazzaniga M. E. +
Stratified analyses refine association between TLR7 rare variants and severe COVID-19 01 - Articolo su rivista 2024 Bonfanti P.Lombardi A.Invernizzi P.Gerussi A.Citerio G.Biondi A.Valsecchi M. G.Cazzaniga M. E.Foti G.Bettini L. R. +
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 01 - Articolo su rivista 2023 Zambelli A.Cazzaniga M.Antonazzo I. C.Mantovani L. G.Cortesi P. A. +
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 01 - Articolo su rivista 2023 Cazzaniga, Marina EBonfanti, Paolo +
A multidisciplinary approach to screen the post-COVID-19 conditions 01 - Articolo su rivista 2023 Squillace N.Rossi E.Bellelli G.Pozzi M.Luppi F.Strepparava M. G.Ferrarese C.Bonfanti P.Bellani G.Biondi A.Cazzaniga M. E.Citerio G.Foti G.Valsecchi M. G.Beretta E. M.Spolti A.Ferlicca D.Bettini F.Bellin V.Meroni V.Gatti S.Bronco A.Ripa C.Sosio S.Faverio P.Monzani A.Ferrara M. C.Zarcone C.Beretta S.Salvarani V. +
A second update on mapping the human genetic architecture of COVID-19 01 - Articolo su rivista 2023 Invernizzi, PietroGerussi, AlessioBiondi, AndreaBellani, GiacomoBellelli, GiuseppeCiterio, GiuseppeFoti, GiuseppeBettini, Laura RacheleValsecchi, Maria G.Cazzaniga, MarinaFaverio, PaolaBonfanti, Paolo +
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 01 - Articolo su rivista 2023 Cazzaniga M. E. +
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 01 - Articolo su rivista 2023 Cordani N.Bianchi T.Cortinovis D. L.Cazzaniga M. E.Lissoni A. A.Landoni F. +
Aromatase inhibitors: the journey from the state of the art to clinical open questions 01 - Articolo su rivista 2023 Cazzaniga M. +